Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, Double-blind, Placebo-controlled Phase 2 Study of DS107 (DGLA) in Moderate to Severe Uremic Pruritus
2017-004098-15Phase 2Terminated
- Sponsor
- DS Biopharma
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease-associated pruritus (CKD-aP) comparing DS107 (DGLA) with Placebo (2 arms). Primary endpoint: Change from baseline in worst itching over the last 24 hours. Started Nov 2017; status: terminated.
02
Drugs
DS107E
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on 2017-004098-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004098-15.